Clinical Cardiac Rehabilitation Registry Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiac Rehabilitation
- Sponsor
- China National Center for Cardiovascular Diseases
- Enrollment
- 2081
- Locations
- 1
- Primary Endpoint
- All-cause and attributed deaths
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Establish an electronic cardiac rehabilitation patient registration system and clinical database, carry out prospective cohort follow-up and observation of cardiovascular disease (CVD) patients receiving cardiac rehabilitation in inpatients and outpatients, collect risk factors, diagnosis and treatment status, rehabilitation diagnosis and treatment, clinical outcomes and follow-up results, and establish a short-term and long-term follow-up mechanism.
Detailed Description
Establish an electronic cardiac rehabilitation patient registration system and clinical database, carry out prospective cohort follow-up and observation of cardiovascular disease (CVD) patients receiving cardiac rehabilitation in inpatients and outpatients, collect risk factors, diagnosis and treatment status, rehabilitation diagnosis and treatment, clinical outcomes and follow-up results, and establish a short-term and long-term follow-up mechanism. Through the real world clinical practice data of cardiac rehabilitation of CVD patients, describe the population and disease characteristics of cardiac rehabilitation patients, the provision of cardiac rehabilitation services and the influencing factors; Analyze and study the key technologies of clinical cardiac rehabilitation, evaluate the implementation quality of cardiac rehabilitation, improve the clinical pathway of cardiac rehabilitation, and optimize the service process.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age and older.
- •Patients receiving inpatient cardiac rehabilitation, and/or participating in outpatient cardiac rehabilitation.
- •All cases selected were in New York Heart Association (NYHA) cardiac function class II and below.
- •Normal troponin.
- •Patients with some ability to communicate and understand.
- •have signed an informed consent form. -
Exclusion Criteria
- •Subjects who are participating in clinical trials of other drugs or devices.
- •Patients with NYHA cardiac function class III or higher.
- •Mentally impaired, or unable to communicate effectively with investigators.
- •Refusal to sign the informed consent form.
Outcomes
Primary Outcomes
All-cause and attributed deaths
Time Frame: 1-year and 2-year
All-cause and attributed deaths during hospitalization and follow-up of CVD patients
Major adverse cardiovascular events (MACE) occurrence
Time Frame: 1-year and 2-year
Major adverse cardiovascular events (MACE) occurrence include cardiovascular death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemia-driven revascularization.
Secondary Outcomes
- Cardiopulmonary function and quality of life(1-year and 2-year)
- Participation and adherence(1-year and 2-year)
- Medical costs of cardiac rehabilitation patients during hospitalization and up to 2 years after discharge.(1-year and 2-year)
- Proportion of different comorbidities, interactions and prognosis in CVD.(1-year and 2-year)